Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers

Overview

The purpose of this study is to determine the pharmacokinetic dose proportionality of 50 μg and 100 μg Clonidine and comparative bioavailability of clonidine with that from the Reference drug, Catapres® 100 μg oral tablets following single dose administration in healthy subjects.

Full Title of Study: “Randomised Single Dose 3 Way Crossover Single Blind Study to Evaluate the Pharmacokinetic Dose Proportionality, Compare the Bioavailability and Safety of Clonidine Mucoadhesive Buccal Tablets (MBT) With Catapres in Normal Healthy Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 2015

Detailed Description

A single blind, randomised, 3-period, 3-sequence single-dose crossover study to determine the pharmacokinetic dose proportionality of Clonidine MBT 50 μg and Clonidine MBT 100 μg and comparative bioavailability of clonidine from the Reference drug, Catapres® 100 μg oral tablets following single dose administration in healthy male and female subjects. 36 subjects will be randomised for 30 to complete the study. The study will comprise of 3 Treatment Periods (1, 2 and 3) and a post study follow up (7 – 12 days after the last dose). Study drug will be administered on the morning of Day 1. Pharmacokinetic (PK) blood samples will be collected for each of three treatment periods. Safety will be evaluated at specified times throughout the study. There will be at least 7 days between dose administrations.

Interventions

  • Drug: Clonidine MBT 50µg
    • Clonidine MBT 50µg, single dose
  • Drug: Clonidine MBT 100µg
    • Clonidine MBT 100µg, single dose
  • Drug: Catapres 100μg
    • Catapres tablet 100μg, single dose

Arms, Groups and Cohorts

  • Experimental: Clonidine MBT 50µg
    • Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
  • Experimental: Clonidine MBT 100µg
    • Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
  • Active Comparator: Catapres 100μg
    • Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.

Clinical Trial Outcome Measures

Primary Measures

  • Dose proportionality of two strengths of clonidine MBT (50μg and 100 μg) as assessed by Non-compartmental pharmacokinetic analysis (Area Under the Curve)
    • Time Frame: 3 Months
    • To evaluate dose proportionality of two strengths (50 μg and 100 μg) of Clonidine MBT, by using Area Under the Curve (AUC)
  • Bioavailability of clonidine from Clonidine MBT 50 μg and 100 μg with that from oral clonidine hydrochloride 100 μg tablets. (Area Under the Curve)
    • Time Frame: 3 Months
    • To compare the bioavailability of clonidine from Clonidine MBT® 50 μg and 100 μg with that from oral clonidine hydrochloride 100 μg tablets, by using Area Under the Curve (AUC)

Secondary Measures

  • General safety information (adverse events, (AEs), 12-lead electrocardiogram (ECG) and vital signs), during the study period.
    • Time Frame: 3 Months
    • Number of Participants With Treatment-Related Adverse Events as Assessed by Common Toxicity Criteria for Adverse Effects (CTCAE v4.0), 12-lead electrocardiogram (ECG) and vital signs

Participating in This Clinical Trial

Main Inclusion Criteria:

  • Healthy males or females (non-pregnant/non-lactating) aged 18 – 50 years. – A Body Mass Index (BMI) of 18-30. – No clinically significant abnormal serum biochemistry, haematology and urine examination values. – A negative urinary drugs of abuse screen. – Negative HIV and Hepatitis B and C results. – No clinically significant abnormalities in 12-lead electrocardiogram (ECG). – No clinically significant abnormalities in blood pressure or pulse. – No allergy or sensitivity to clonidine or any of its excipients. – No allergy to milk or milk derivatives. – Subjects must provide written informed consent to participate in the study Main Exclusion Criteria:

  • Current or past medical condition that might significantly affect the pharmacokinetic or – pharmacodynamic response to clonidine. – Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the previous 30 days. – Pathological condition of the oral cavity that would affect administration via the buccal route. – Raynaud's disease or other peripheral vascular disease. – Receipt of regular medication within 14 days of the first dose that may have an impact on the safety and objectives of the study (at the Investigator's discretion). – Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction. – Symptomatic postural hypotension evident on screening – History or evidence of Suicidal Ideation and/or behaviour as determined by using Columbia-Suicide Severity Rating Scale (C-SSRS)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Onxeo
  • Collaborator
    • Simbec Research
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Girish Sharma, MD, Principal Investigator, Simbec Research

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.